Immunomedics’ Epratuzumab Enters Phase III Trials For Lupus
This article was originally published in The Pink Sheet Daily
Executive Summary
The B-cell modulator is beginning pivotal trials in patients with moderately active systemic lupus erythematosus and in patients with severe SLE flares. Other investigational lupus therapies have been held up by Phase III failures.